California Public Employees Retirement System boosted its stake in shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 3.3% during the 4th quarter, HoldingsChannel reports. The firm owned 68,100 shares of the company’s stock after buying an additional 2,200 shares during the quarter. California Public Employees Retirement System’s holdings in Pacira Pharmaceuticals were worth $3,109,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bouchey Financial Group Ltd purchased a new position in Pacira Pharmaceuticals during the fourth quarter valued at $205,000. Fisher Asset Management LLC purchased a new position in Pacira Pharmaceuticals during the fourth quarter valued at $241,000. Oppenheimer Asset Management Inc. lifted its position in Pacira Pharmaceuticals by 207.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 7,375 shares of the company’s stock valued at $277,000 after purchasing an additional 4,976 shares in the last quarter. Stifel Financial Corp purchased a new position in Pacira Pharmaceuticals during the third quarter valued at $353,000. Finally, SG Americas Securities LLC lifted its position in Pacira Pharmaceuticals by 65.1% during the third quarter. SG Americas Securities LLC now owns 10,559 shares of the company’s stock valued at $396,000 after purchasing an additional 4,164 shares in the last quarter.
In other news, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total value of $1,160,888.15. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 6.60% of the company’s stock.
Shares of Pacira Pharmaceuticals stock opened at $30.90 on Monday. Pacira Pharmaceuticals Inc has a twelve month low of $29.35 and a twelve month high of $52.47. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.96 and a quick ratio of 6.22. The stock has a market capitalization of $1,258.00, a PE ratio of -28.35 and a beta of 1.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Wednesday, February 28th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The firm had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. During the same period in the previous year, the firm posted $0.09 earnings per share. The business’s revenue was up 8.5% compared to the same quarter last year. research analysts anticipate that Pacira Pharmaceuticals Inc will post -0.58 EPS for the current fiscal year.
PCRX has been the topic of several analyst reports. ValuEngine upgraded Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Canaccord Genuity set a $42.00 target price on Pacira Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, November 29th. HC Wainwright set a $55.00 target price on Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, January 4th. BMO Capital Markets lowered their target price on Pacira Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research report on Thursday, March 1st. Finally, Wedbush reiterated a “buy” rating and set a $80.00 target price on shares of Pacira Pharmaceuticals in a research report on Monday, November 20th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $45.29.
ILLEGAL ACTIVITY WARNING: “California Public Employees Retirement System Grows Stake in Pacira Pharmaceuticals Inc (PCRX)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/19/california-public-employees-retirement-system-grows-stake-in-pacira-pharmaceuticals-inc-pcrx.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.